Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA
Arye Rubinstein(Albert Einstein College of Medicine), Leman Yel(Children's Hospital of Philadelphia), Donald McNeil, Sudhir Gupta(University of California, Irvine), Niraj Patel(Levine Children's Hospital), Paz Carrasco(Baxalta (United States)), András Nagy(University of Szeged), Mohsen Mabudian, Richard L. Wasserman(ENT and Allergy)
Cited by 1
Related Papers
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
|Journal of Allergy and Clinical Immunology|2018|261
Role of NF-κB signaling pathway in increased tumor necrosis factor-α-induced apoptosis of lymphocytes in aged humans
|Cell Death and Differentiation|2005|83
Mutations in topoisomerase IIβ result in a B cell immunodeficiency
|Nature Communications|2019|58
Outcomes of Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) — National Neonatology Forum (NNF) India COVID-19 Registry
|Indian Pediatrics|2021|52
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
|European Journal of Pharmaceutical Sciences|2009|48